Key Points (tl;dr)
Brain and mental health is one of the largest, fastest-growing opportunity sets in global healthcare — and the science, technology, and capital are finally converging.The market is maturing: capital is concentrating on companies that deliver real clinical outcomes alongside sustainable economics.Awareness Capital is purpose-built for this moment: a specialist fund that invests across the full landscape of brain and mental health, and reinvests in the ecosystem that makes great companies possible.
----
Think about the people you love. Chances are, at least one of them has been touched by depression, anxiety, dementia, Parkinson’s disease, addiction, or psychosis. Not as a statistic — as a reality. Lost years. Lost productivity. Lost relationships.
Brain and mental health conditions are not a niche corner of healthcare. They are ubiquitous, woven into the fabric of human life. They shape how we think, work, parent, age, grieve, and connect. They span a wide ranging spectrum of conditions — psychiatric, neurological, neurodegenerative, neurodevelopmental, cerebrovascular — and they reach far beyond the clinic, into our schools, our workplaces, our housing, our communities. Anxiety and depression are among the leading drivers of disability globally, alongside neurological conditions such as stroke, dementia, and migraine— and their burden continues to rise due to population ageing and epidemiological transition.
The market reflects this reality: over $5 trillion globally and growing. But this is not primarily a market story. It is a human story — our story — and the science, technology, and capital needed to change its ending are within reach.
The Science Is Opening New Possibilities
For decades, the gap between what we understood about the brain and what we could actually do about it was humbling. We knew these diseases were real. We knew they were devastating. We invested billions in research. And yet, after decades of scientific progress, outcomes have barely moved.
That is changing, faster than most people realise.
The last decade has delivered genuine, practice-changing breakthroughs. To list just a few examples: we’ve seen the first FDA-approved disease-modifying treatments for Alzheimer's (Leqembi, Kisunla); the first FDA-approved pharmacological intervention for schizophrenia in over 50 years (Cobenfy); psychedelic-assisted therapies are advancing rapidly through clinical trials, with psilocybin showing strong Phase 2 and 3 data for depression and PTSD, and esketamine already FDA-approved for treatment-resistant depression; next-generation neurostimulation expanding access to non-pharmacological care; a revolution in biomarkers is finally letting us detect disease before it becomes disaster (see Alzheimer's blood test and Laguna Diagnostics test for schizophrenia and bi-polar); and digital biomarkers — from speech pattern analysis to wearable-derived physiological signals — are opening a new frontier in psychiatric prediction, moving us closer to detecting illness before it fully emerges. Now add AI — transforming drug discovery, diagnosis, and care delivery simultaneously — and other enabling technologies that are compressing what used to take generations into years.
The founders of companies in this space are not chasing trends. They are following the science, and the science is ready.
Big pharma knows it too. In the first ten months of 2025, CNS and neurology deals overtook oncology as the leading category in pharma M&A. In 2023 alone, deal value in the central nervous system (CNS) space surpassed $30 billion, with landmark acquisitions including BMS-Karuna ($14B), AbbVie-Cerevel ($9B), and Biogen-Reata ($7B). J&J's $14.6 billion purchase of Intra-Cellular Therapies was the single largest biopharma deal of 2025 — a signal that neurodegenerative disease and psychiatric disorders are among the most strategically important areas in all of medicine. The era of pharma avoiding brain and mental health would seem to be coming to an end.
A Market Coming of Age
As one of our Advisors Tom Insel has argued in his book Healing, the early wave of mental health investment — from 2016 to 2022 — was largely about access: getting people into care, however they could get there. Telehealth, therapy apps, employee wellness platforms. Access was always necessary but never sufficient — the harder problem was never getting people through the door, but what happened once they got there. That wave has now normalised. Global venture funding for mental health has settled at around $1 billion per year; early-stage deal volume has contracted; capital is concentrating — just 5% of companies have raised 55% of available venture funding (as presented by Steve Duke of The Hemingway Report at MHIN UK, April 2026.)
This is a market finding its footing. Early-stage deal volume has tightened, but the quality of what remains is higher — companies with genuine clinical evidence, defensible business models, and a clear line from patient benefit to economic return. That is a more durable foundation for the decade ahead.
This is the market Awareness Capital was built for.
A Different Kind of Investor
What the early wave has also demonstrated is that this sector does not reward generalists. The regulatory pathways are complex. The outcome measures require clinical sophistication. The business models span science, care delivery, and reimbursement in ways that most investment frameworks were not built to navigate — which is why even the most sophisticated generalist funds have found it difficult to develop the depth this category demands.
In the most scientifically complex investment categories — oncology, genomics, infectious disease — the funds that have shaped those markets (e.g. OrbiMed, Third Rock, and Flagship Pioneering) were built around deep specialist conviction, not generalist attention. The same logic holds beyond healthcare: Generation Investment Management was founded on the conviction that the transition to a sustainable economy required a dedicated, systemic investor — one who understood the science, the policy, and the economics of climate simultaneously — not a generalist who happened to notice climate. Awareness Capital was founded on the same logic for brain and mental health. In a sector where specialist VCs remain rare, we are purpose-built to invest across the full landscape: from compounds, devices, and digital platforms; to early clinical and commercial scale; therapeutics, care delivery, and the AI infrastructure connecting them.
In a little over two years, Awareness has invested in 15 portfolio companies. None have been marked down. Many have been marked up, and there has been one successful exit. Two companies have since received eight-figure equity investments from Fortune 500 companies — the same incumbents racing to build neuroscience portfolios through M&A, validating the judgement of those who backed them early.
For even the most experienced capital allocators, these results signal something exceptional. It is increasingly evident that industry giants are taking notice of our early-stage convictions, providing powerful market validation of the assets we have helped build (see Talkspace’s acquisition of our portfolio company Wisdo, which has more recently been acquired by UHS).
While our journey is just beginning, the momentum behind our path is undeniable.
Returns and Impact Are Not in Tension
Awareness stands out not just in what we invest in, but in how we participate in the ecosystem.
Awareness Capital differs from conventional venture in one structural way: a meaningful portion of GP carry in Fund I is committed to reinvesting back into the brain and mental health ecosystem — supporting non-profit organisations like One Mind. (Fund II will aim to replicate this model, expanding to support other ecosystem catalysers, such as Kokoro.)
This is not philanthropy bolted on as an afterthought. It reflects a conviction about how this sector actually works. Non-profits, academic groups, and community organisations fund early research, support underserved populations, generate the data that de-risks commercial investment, and often act as the proving ground for new models of care. A stronger ecosystem produces better companies. The portfolio and the ecosystem are not separate things — they grow together.
The stakes make this hard to ignore. Median government spending on mental health conditions hovers at around just 2% of total health budgets globally, producing an annual funding gap of $200 to $350 billion. Meanwhile, each dollar invested in scaling mental health interventions generates an estimated $5 to $6 in economic return. And McKinsey estimates that coordinated, proactive investment in brain and mental health could unlock $6.2 trillion in cumulative global GDP gains by 2050. That is not an abstraction. It is the value of people living full lives — working, connecting, contributing — rather than losing years to illness that could have been treated, or never developed at all.
Returns and impact are not in tension here. They are the same bet.
The science is ready. The companies are here. The capital is beginning to move.
Awareness Capital exists because the people who need this — such as our loved ones, and the hundreds of millions of people we don’t know — cannot afford for us to move slowly.
In brain and mental health, waiting is not a neutral act.
--
With thanks to fellow travelers, Charlie Finnie, Gwill York, Tom Insel, Steve Duke, and Harris Eyre for their review and suggested edits (and camaraderie).